•  
  •  
  •  
  •  

2026-05-23 18:16:04

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Bajaj Broking Weekly FII and DII Commentary for 23rd May 2026
  • TCC Concept Ltd delivers strong FY26 Growth
  • Gokaldas Exports consolidated FY26 Total Income up by 4% YoY
  • Trigyn Technologies Ltd - Result Highlights for Q4, FY26
  • Excelsoft Technologies Reports Strong Q4 & FY26 Performance

Keywords Selected:  Laboratories

Research

  • Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY
  • BUY Ipca Laboratories - Q4FY22 Result Update - Weak exports; gradual recovery

IPO News

  • Ambey Laboratories Ltd IPO to open for subscription on July 4, 2024
  • Valiant Laboratories Ltd to raise funds through IPO

Stock Report

  • Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India
  • Caplin Point Laboratories Ltd Q4 FY2026 consolidated PAT higher at Rs. 170.11 crores
  • Dr. Reddy's Laboratories Limited recommends final dividend of Rs. 8
  • Neuland Laboratories Ltd recommends final dividend of Rs. 34
  • Dr. Reddys Laboratories Ltd consolidated Q4 FY2025-26 PAT slides to Rs. 220.1 crores
  • Neuland Laboratories Ltd consolidated Q4 FY26 PAT surges to Rs. 212.67 crores
  • US FDA Inspection at Alkem Laboratories Ltd's CRO facility located at Taloja
  • Dr. Reddy's and Nestlé Health Science strengthens presence in diabetes & obesity nutrition space with Celevida® GLP+ launch
  • Auro Laboratories Ltd receives Certification of Substances Department from EDQM
  • Auro Laboratories Ltd receives Certificate of GMP Compliance of a Manufacturer from Swissmedic
  • Caplin Steriles Ltd gets USFDA approval for Calcium Gluconate Injection
  • US FDA Inspection at Alkem Laboratories Ltd's manufacturing facility located at Amaliya, Daman
  • Colinz Laboratories Ltd Q4 FY2026 PAT up at Rs. 17.12 lakhs
  • OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval for Generic Semaglutide Injection
  • Morepen Secures Fourth Consecutive USFDA Inspection with Zero Observations
  • Unichem Pharmaceuticals (USA) Issues Voluntary Recall of Buspirone Hydrochloride Tablets
  • Alkem launches A to Z Daily, an everyday multivitamin supplement for body and mind
  • Strategic Manufacturing Agreement between Valencia Beverages and Superwaters P Ltd and Virchow Laboratories Ltd
  • Alkem Laboratories Doubles Investment for Ujjain Greenfield Facility
  • Saharsh Davuluri takes over as CEO & MD of Neuland and will lead the next phase of CDMO expansion
  • Coral Laboratories Ltd commissions expanded capacity at Dehradun Plant
  • Dr. Reddy's Laboratories announces launch of India's first DCGI-approved Semaglutide injection 'Obeda®' for Type 2 Diabetes
  • Caplin Steriles gets USFDA approval for Potassium Phosphates Injection
  • Ind-Swift Laboratories Earns EcoVadis Silver Medal for Sustainability Excellence

Industry News

  • Hamdard invests in SIG's aseptic carton technology to meet diverse consumer demands

Latest Post

  • Bajaj Broking Weekly FII and DII Commentary for 23rd May 2026
  • TCC Concept Ltd delivers strong FY26 Growth
  • Gokaldas Exports consolidated FY26 Total Income up by 4% YoY
  • Trigyn Technologies Ltd - Result Highlights for Q4, FY26
  • Excelsoft Technologies Reports Strong Q4 & FY26 Performance


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025